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Epigenetic Silencing of Lysyl Oxidase-Like-1 through
DNA Hypermethylation in an Autosomal Recessive
Cutis Laxa Case
Romain Debret1, Vale´rie Cenizo2, Ge´raldine Aimond1, Vale´rie Andre´2, Martine Devillers3, Isabelle Rouvet4,
Andre´ Me´garbane´5, Odile Damour1 and Pascal Sommer1
We have recently reported a case of cutis laxa caused by a fibulin-5 missense mutation (p.C217R). Skin
fibroblasts from this individual showed an abnormal pattern of expression of several genes coding for elastic
fiber-related proteins, including lysyl oxidase-like-1 (LOXL1). In this study we intended to elucidate the
mechanism responsible for LOXL1 downregulation in these fibulin-5-mutant cells. We identified a proximal
region (442/342) of the human LOXL1 promoter in which two binding sites for the transcription factor
specific protein 1 (Sp-1) are required for gene activity in normal fibroblasts. Binding of Sp-1 to these sequences
was dramatically reduced within cutis laxa cells, although Sp-1 expression was normal. Further analysis of the
promoter sequence found increased methylation levels in cutis laxa cells compared with cells from unaffected
individuals. When DNA methyltransferase activity was transiently inhibited in cutis laxa cells using the 5-aza-20-
deoxycytidine, we found a significant increase in LOXL1 expression. In conclusion, besides changes caused by
the fibulin-5 mutation, LOXL1 gene regulation is affected by an epigenetic mechanism that can be reversed by
an inhibitor of DNA methyltransferase activity. It is not yet known whether LOXL1 gene expression is affected in
all cases of cutis laxa arising from fibulin-5 mutation.
Journal of Investigative Dermatology (2010) 130, 2594–2601; doi:10.1038/jid.2010.186; published online 8 July 2010
INTRODUCTION
Lysyl oxidase-like 1 (LOXL1) enzyme belongs to the lysyl
oxidase (LOX) family involving five related members: LOX,
LOXL1, LOXL2, LOXL3, and LOXL4 (Kagan and Li, 2003).
They show highly similar sequences in their catalytic
C-terminal regions, whereas their N-terminal regions are
unique. This would suggest identical enzymatic activities but
different patterns of expression and secretion. LOX, the best
characterized isoform, was first identified as the enzyme
responsible for crosslinking type I collagen and elastin in vitro
(Kagan and Trackman, 1991). More recently, the role of
LOXL1 in elastin crosslinking has also been shown in vitro
(Borel et al., 2001) and its association with human skin elastic
fibers confirmed (Noblesse et al., 2004). Mice deficient in
LOXL1 do not deposit normal elastic fibers and present many
tissue defects, such as enlarged airspaces of the lung, loose
skin, and vascular abnormalities. In addition, post
partum reconstruction of uterine elastic tissue is impaired in
LOXL1/ female mice and prolapse of the pelvic organs is
observed (Liu et al., 2004). Immunohistochemical studies
during development and growth of mouse tissues underlined
the fact that despite LOXL1 being present in most major
organs in late fetal and newborn mice, it generally diminishes
as animals age (Hayashi et al., 2004). A decrease in LOXL1
levels has also been correlated with aortic fragility in the rat
because of a defect in collagen and elastic fibers remodeling
(Behmoaras et al., 2008). These data highlight the importance
of LOXL1 in elastogenesis during development and aging.
For normal assembly of elastic fibers, the N-terminal
region of LOXL1 is required to localize the enzyme to elastic
fibers (Thomassin et al., 2005) and to bind fibulin-5, which
facilitates elastin polymerization onto the microfibril scaffold
(Liu et al., 2004; Kielty, 2006).
Cutis laxa-related homozygous inherited mutations in the
gene for fibulin-5 are considered as null mutations with
respect to the role of fibulin-5 in elastic fiber formation
because of decreased interaction between tropoelastin and
fibrillin-1 (Hu et al., 2006). We have reported two cutis laxa
cases for a brother and sister from a consanguineous Lebanon
family with autosomal recessive transmission (Claus et al.,
2008). The 9-year-old boy presented with bilateral inguinal
hernias at birth. At 1 month, the parents noticed redundant
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loose skin, especially evident on the face, the abdomen, and
the dorsum of the hands and feet. We discovered a
homozygous missense mutation (c.649T-C; p.C217R) in
the fibulin-5 gene (FBLN5). Fibroblast cultures obtained
from one biopsy showed low expression levels of elastic
fiber-related genes, particularly LOXL1, fibrillin-1 (FBN1),
and elastin (ELN).
In this study, we investigate the mechanisms leading to
low LOXL1 expression in fibulin-5 C217R cells. The
identification of a molecular pathway occurring as a result
of this mutation would offer a pharmacological approach for
treating the consequences of this particular cutis laxa
genotype.
RESULTS
LOXL1 is downregulated in FBLN5 (p. C217R) cutis laxa cells
To evaluate LOXL1 steady-state mRNA expression level in
cutis laxa cells, we performed real-time reverse transcription-
PCR experiments on skin fibroblasts from a 9-year-old male
patient with fibulin-5 mutation C217R (Claus et al., 2008). A
group of five skin fibroblast strains obtained from healthy
children (3 girls and 2 boys, 8–10 years of age) served as the
control. At 2 days after confluence, which is required for
optimum LOXL1 mRNA expression (Thomassin et al., 2005),
LOXL1 mRNA levels in cutis laxa cells were approximately
half (52%) of that in the control healthy cells (Figure 1a).
Western blotting (Figure 1b) of lysates from 8-day post-
confluent cultures detected the 66 kDa LOXL1 proenzyme
and a minor band with an apparent molecular weight of
B80 kDa. The nature of the larger band is unknown, but is
likely a noncovalent complex containing LOXL1. Semiquan-
titative analysis of the 66 kDa LOXL1 band showed a trend
toward lower levels (42%, Po0.057; normalized to b-actin)
in cutis laxa cells compared with the four healthy strains
(Figure 1b). This correlation between transcript and protein
expressions raises the possibility that LOXL1 gene transcrip-
tion is lower in cutis laxa cells.
Characterization of the human LOXL1 promoter
To define whether the low expression level of LOXL1 mRNA
and protein in cutis laxa could be explained by transcrip-
tional mechanisms, we cloned and modified the human
LOXL1 promoter. The complete promoter sequence as well
as deletion constructs described below were cloned inframe
to a luciferase gene reporter to determine the DNA sequences
responsible for its basal activity. For cloning and defining the
initiation of translation (defined as the þ 1 nucleotide), the
50 untranslated region sequence NM_005576 (GenBank,
National Center for Biotechnology Information), was aligned
with the NC_000015 sequence of human chromosome 15.
The 2172/þ1 region of LOXL1 (called hPrLOXL) was
amplified using specific primers from genomic DNA of
human dermal fibroblasts (see Supplementary Table S1
online) and inserted in front of the luciferase gene reporter.
In the absence of a TATA box, the presence of consensus sites
for the binding of the transcription factor specific protein 1
(Sp-1) on GC boxes in its most proximal zone (712/þ 1)
suggests that Sp-1 could have a role in transcription initiation
(Figure 2a). Several other putative regulatory sites were
localized on the promoter sequence using the TRANSFAC
software (Biobase, Germany, www.gene-regulation.com).
The luciferase activity of serially deleted hPrLOXL-carry-
ing constructs was first defined in healthy dermal fibroblasts
(Figure 3a). The 2172/þ1 sequence was used as a
reference. The 2172/2151 and 712/391 regions
contain transcription activators, as their deletion resulted in
a reduced activity of the corresponding constructs (2151
and 391). In contrast, deletion of the 2002/1438 region
led to an increase in the hPrLOXL activity (1438/þ 1
construct). The shorter constructs (391/þ1 and 81/þ 1)
had almost no activity. Hence, the promoter 712 (712/
þ 1) was sufficient to maintain a strong transcriptional
activity. This region contains most of the Sp-1 binding sites.
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Figure 1. Decreased expression of lysyl oxidase-like-1 (LOXL1) in cutis laxa.
(a) At 2 days after confluence, monolayers of skin fibroblasts from cutis laxa
patient (Cutis Laxa) or from five age-matched healthy children (Healthy) were
analyzed by real-time PCR. b-Actin transcript was used for normalization. For
the healthy group, results represent the average over the five strains (n¼ 6 per
strain), and cutis laxa results represent three independent experiments
performed in triplicate. Results are expressed as mean±SEM (**Po0.01,
Wilcoxon test). (b) Skin fibroblasts were grown after confluence for 8 days
before western blotting. Immunodetection of b-actin was performed to ensure
equal protein loadings. The experiment was performed twice. Samples in the
three cutis laxa lanes were obtained from three different extractions at three
different passages.
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To clarify the importance of the 712/þ 1 region, we
created deletions in the 712 construct by targeting
the region close to the putative transcription initiation site
(Figure 3b). The first deletion (712D(442/418)) consisted
of a putative estrogen response element site, whereas the two
Sp-1 sites (Sp-1A and Sp-1B) were conserved. Using this
construction, a slight decrease in the mean value (25%) was
observed when compared with the native 712 (712/þ 1)
construct. The second deletion of the 442/342 region
covered the putative estrogen response element site and the
two putative Sp-1 binding sites. The resulting 712D(442/
342) showed a strong and significant decrease in luciferase
activity. Interestingly, the 391 (391/þ 1) construct, con-
taining the Sp-1B site only, resulted in luciferase activity
similar to the 712D(442/342) construct. Competitive
electrophoretic mobility shift assays were therefore
performed to characterize Sp-1 binding activity onto
the sequence 415/353 (called phLL), which appeared
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Figure 2. The human lysyl oxidase-like-1 (LOXL1) promoter sequence shows GC-rich motifs in its proximal region but no TATA box. (a) The hPrLOXL
sequence was obtained by pairwise alignment of LOXL complementary DNA (cDNA) with the human chromosome 15 sequence. The promoter contains
numerous specific protein 1 (Sp-1) sites in its most proximal zone 712/1. Other consensus sites recognized by transcription factors have been identified: GRE
(glucocorticoid response element); T3R-b/RXR-a (heterodimer thyroid hormone receptor/retinoic acid receptor); CTF (CCAAT-binding factor); EGF response
element; estrogen receptor/Sp-1; CACCC binding protein; TPA response element (activator protein-1 (AP-1) binding); CRE-BP1 (cAMP response element-binding
protein-1); NF-1; YY1-NFE-1; Lyf-1; E box; AML1/NF-Atp; and GATA-1. Putative transcription initiation sites are indicated by arrowheads. (b) The 494/323
promoter region containing two Sp-1 and one estrogen response element (ERE) half-site.
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essential for the hPrLOXL activity. Nuclear protein extracts
from healthy fibroblasts were subjected to analysis in the
presence of the radiolabeled phLL probe alone (Figure 4b,
lane 2). The most intense upper band and the third band
disappeared after a specific competition with an unlabeled
Sp-1 consensus probe (lane 3), whereas the shifted bands
remained unchanged in the presence of an unlabeled
activator protein-1 consensus probe used as a nonspecific
competitor (lane 4). Identification of Sp-1 complexes was
assessed by a supershift assay using a specific antibody raised
against Sp-1. Our results show that Sp-1 DNA binding
corresponds to the upper band that strongly decreased,
whereas two slight supershifted bands appeared as indicated
by asterisks (lane 5). The two supershifted complexes can be
explained by the binding of one or two Sp-1 proteins
simultaneously at two distinct sites. In contrast, the third
protein–DNA complex inhibited by specific competition
(sharp symbol) was not recognized by Sp-1 antibody,
suggesting the binding of nonrelated factors. In conclusion,
the 415/353 phLL sequence can bind Sp-1 protein.
Sp-1 binding onto the essential region of the LOXL1 promoter is
not observed in cutis laxa cells
To establish whether modulation of LOXL1 gene activation
coincides with a Sp-1 binding defect in cutis laxa fibroblasts,
we used the chromatin immunoprecipitation approach using
an antibody raised against Sp-1, followed by a classical PCR
amplification with primers specific for the 494/323
sequence (see Supplementary Table S1 online). As shown
in figure 4c, chromatin immunoprecipitation analyses of
fibroblast DNA revealed that Sp-1 binding to the LOXL1
promoter (494/323) region was not detectable in cutis
laxa fibroblasts, whereas such an association was observed in
fibroblasts from healthy children (Figure 4c). Western blotting
experiments confirmed the presence of Sp-1 in nuclei of post-
confluent cutis laxa and healthy fibroblasts strains (Figure 4d).
LOXL1 promoter undergoes hypermethylation in its proximal
region
One hypothesis that could explain a change in Sp-1 binding
activity concerns DNA modifications, such as cytosine
methylation, resulting in a Sp-1 binding defect (Clark et al.,
1997). We therefore investigated the methylation status of
cutis laxa DNA in the LOXL1 promoter sequence. Computer-
ized analysis of the 3500/þ 1 sequence of LOXL1 promoter
highlighted a small CpG island, spanning nucleotides 398
to 212, suggesting potential methylation site (Figure 5a).
Bisulfite modification and PCR-based methylation assays on
the (506/115) region were performed (Figure 5b). We
observed that all of the cytosines within this region in healthy
strains had been converted to uracil residues by the bisulfite
agent, indicating the absence of methyl groups (open circles).
In contrast, in cutis laxa fibroblasts, several cytosines were
resistant to uracil conversion within the CpG island, showing
that these cytosines were methylated in cutis laxa DNA
(closed circles). These results indicate that methylation
occurs in the CpG island of LOXL1 promoter in cutis laxa
cells at a higher rate than in fibroblasts from healthy donors.
DNA methylation is generally associated with a transcrip-
tional repression of the targeted gene. Hence, removing
methylation from CpG sites would permit to restore the
normal activity of the LOXL1 promoter.
LOXL1 expression is restored by DNMT inhibition
In mammals, DNA methylation is mainly catalyzed by three
DNA methyltransferases (DNMTs): DNMT1, DNMT3a, and
DNMT3b. DNMT is a family of proteins responsible for the
attachment of a methyl group to the 5-position of the cytosine
ring when it is followed by a guanosine residue (Goll and
Bestor, 2005). Subconfluent cutis laxa cells were treated for
5 days with the DNMT inhibitor 5-aza-20-deoxycytidine
(5aza-dC) and further grown until postconfluent for 2 days.
This 5aza-dC treatment induced a 2-fold increase in the
LOXL1 mRNA level (Figure 6). No effect of 5aza-dC was
observed on LOXL1 mRNA expression levels in healthy cells
(not shown). The 5aza-dC treatment also induced a 2.5-fold
increase in ELNmRNA expression, whereas neither FBN1 nor
LOX mRNA expression levels were modified (Figure 6).
DISCUSSION
This work identifies cytosine methylation of the LOXL1
promoter as a regulatory mechanism in skin fibroblasts from a
cutis laxa patient but not healthy donors. Because cytosine
Luciferase activity (% relative to full length –2172/+1)
Luciferase activity (% relative to full length –2172/+1)
Sp-1A
–712
–712
–712
–391
Δ[–442/–418]
Δ[–442/–342]
Sp-1B luc
luc
luc
luc
0 50 100 150 200
n=10
n=10
n=10
n=6
n=8
n=6
n=8
n=3
n=6
n=3
n=6
NS
NS
NS
NS
NS
NS
*
*
*
**
*
*
*
*
n=4
–2172/+1 - luc
–2151/+1 - luc
–2002/+1 - luc
–1438/+1 - luc
–968/+1 - luc
–712/+1 - luc
–391/+1 - luc
–81/+1 - luc
0 100 150 20050
½ERE
Figure 3. The 442/342 region of the proximal lysyl oxidase-like-1
(LOXL1) promoter is required for promoter activity. Luciferase activities at
48 hours after transfection were normalized to b-galactosidase activity
reporter and compared with the longest promoter 2172. (a) Luciferase
activity under the control of different promoter constructs was assessed in
healthy fibroblasts. (b) Deletion effects on the 712 promoter activity in
healthy fibroblasts. A 100-bp deletion of estrogen response (ER) and two
specific protein 1 (Sp-1) binding sites (712D(442/342)) resulted in a
strong decrease in promoter activity. The 25-bp deletion of the ER binding site
alone (712D(442/418)) led to a moderate (25%) decrease in promoter
activity. Statistical tests were performed using one-way analysis of variance
(ANOVA). *Significant; 1=2ERE, estrogen response element half-site;
NS, not significant.
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methylation can have a positive or negative effect on gene
transcription (Jones and Takai, 2001), our observations
suggest a mechanism responsible for LOXL1 downregulation
in this cutis laxa case.
No functional analysis of the LOXL1 promoter has been
undertaken until now, although potential GC boxes for Sp-1
protein binding have been described (Kim et al., 1995). We
therefore defined the main DNA sequences necessary for
LOXL1 promoter activity under normal conditions. We
assigned Sp-1 as an activator of LOXL1, as the deletion of
two consensus binding sequences (Sp-1A and Sp-1B) led to a
dramatic decrease in promoter activity. In the absence of a
functional TATA box, the binding of Sp-1 transcription factor
to proximal GC-rich regions is considered as the main
inducer to recruit the transcriptional machinery (Lania et al.,
1997; Li et al., 2004). Interestingly, the ELN gene, which is
also strongly downregulated in fibulin-5 C217R fibroblasts
(Claus et al., 2008), is similar to LOXL1 in that its promoter
does not contain TATA and CAAT boxes but does contain
several Sp-1 binding sequences, which are involved in its
positive response to insulin growth factor-1 (Jensen et al.,
1995; Conn et al., 1996). In contrast, LOX, a gene less
affected by the fibulin-5 C215R mutation, contains five Sp-1
binding sites in its 50 flanking region and functional TATA and
CAAT boxes (Hamalainen et al., 1993). Altogether, our
findings support the hypothesis that Sp-1 activity in fibulin-5
C217R fibroblasts influence LOXL1 and eventually ELN
expression.
No significant difference in Sp-1 protein content within
fibroblast nuclei from healthy or pathologic cell strains was
observed. However, we showed cytosine methylation sites
within the LOXL1 promoter in cutis laxa cells that were not
methylated in their healthy counterpart. More precisely, CpG
369 in the Sp-1B site was methylated and two tandem Sp-1
sites (245 and 256) are adjacent to several methylated
CpG sequences. The role of cytosine methylation in gene
regulation has been well documented. A decrease in Sp-1
transcription factor affinity and inhibition of Sp-1 binding to
its recognition sequence through cytosine methylation has
been reported (Clark et al., 1997). Methylation of adjacent
CpG motifs also contributes to Sp-1 binding inhibition in vivo
(Zhu et al., 2003). In both cases, one explanation could be
that MeCP2, a repressor of transcription, recognizes methy-
lated CpG motifs and counteracts Sp-1 binding by DNA
accessibility competition (Kudo, 1998). Modification of the
cytosine methylation status is mostly associated with a
malignant transformation of cells (Robertson, 2005). It also
contributes to organ or cell-specific regulation and differ-
entiation during development and notably through inhibition
of Sp-1 binding (Cao et al., 2000; Butta et al., 2006). A high
DNA methylation status can also reflect a condensed state of
chromatin that prevents the binding of transcription factors
(D’Alessio and Szyf, 2006). We showed that deletion
of the Sp-1A site induced the most important decrease in
LOXL1 promoter activity. However, this site was not
methylated when analyzed by bisulfite modifications, but
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Figure 4. Binding of specific protein 1 (Sp-1) on the proximal lysyl oxidase-like-1 (LOXL1) promoter region is impaired in cutis laxa. (a) The 415/353
region of the LOXL1 promoter used as radiolabeled probe in electrophoretic mobility shift assay (EMSA). (b) Unlabeled consensus Sp-1 (lane 3) or
unlabeled consensus activator protein-1 (AP-1; lane 4) were used as specific and nonspecific competitors, respectively. Sp-1 complexes were identified by
supershift using an anti-Sp-1 antibody (lane 5) or normal rabbit IgG as a negative control (lane 6). *Supershifted band; #nonspecific binding. (c) Chromatin
extracted from healthy or cutis laxa cells was immunoprecipitated or not (inputs) and primers specific for the 494/323 region were used for PCR. (d) Sp-1
content in nuclear extracts was assessed by western blotting. In c and d, one extraction from cutis laxa cells is representative of two independent extractions.
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many methylations were detected on adjacent CpG se-
quences, within the Sp-1B site. These observations support an
inactivated state of chromatin in this region explaining why
no binding of Sp-1 was detected by chromatin immunopre-
cipitation.
DNA hypermethylation can be reversed through the use of
DNMT inhibitors such as 5aza-dC. When 5aza-dC was used
on the fibulin-mutant cells, an increase in LOXL1 and ELN
expression to levels found in healthy cells was obtained; this
implies that LOXL1/ELN gene downregulation in cutis laxa
occurs through hypermethylation of promoter sequences. It is
noteworthy that DNMT inhibitors have been clinically used
in phase II in cancer chemotherapy (Goffin and Eisenhauer,
2002), in which they showed antitumoral activities on
nonsolid tumors such as leukemia, and restored antionco-
genes. But efficiency of DNMT inhibitors on tumors is also
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Figure 5. DNA methylation status of lysyl oxidase-like-1 (LOXL1) promoter is increased in cutis laxa. (a) Distribution of the CpG sites in the 3500
promoter region from ATG of LOXL1. A graph of the percentage of CpG observed divided by the expected frequency and a graph of putative CpG islands.
Dinucleotide frequencies were calculated in 200-nucleotide windows moved at 100-nucleotide intervals. The ratio (CpG-% observed/CpG-% expected)
indicated that the 398/212 region contains a CpG island encompassing the second specific protein 1 (Sp-1) binding site (Sp-1B, Figure 2b). (b) DNA
sequences obtained after bisulfite modifications were amplified by high-fidelity PCR and cloned. Four clones for each strain were analyzed by sequencing. Open
circle, unmethylated CpG site; closed circle, methylated CpG site.
www.jidonline.org 2599
R Debret et al.
Epigenetic Downregulation of LOXL1
assigned to cytotoxicity through their contribution to cell
growth inhibition. Consistent with these results, we observed
that the 5aza-dC treatment inhibited cell proliferation of
fibulin-5-mutated cells (not shown). In addition to an intrinsic
toxicity of the 5aza-dC compound, its positive effect on
elastin expression may also contribute to a reduced
proliferation rate (Karnik et al., 2003).
In the fibulin-5 C217R cutis laxa cells, LOXL1 and ELN
were both downregulated (Claus et al., 2008), suggesting the
existence of common regulation mechanisms for both genes.
Similar examples of coordination have been described for
other elastic fibers components, such as FBLN5 and ELN
(Tsuruga et al., 2004). The identification of epigenetic
mechanism leading to LOXL1 downregulation offers a
possible explanation for such coordination. Epigenetic
mechanisms are known to be involved in the regulation of
expression of extracellular matrix components (Chen et al.,
2009; Hardie et al., 2009). However, attributing LOXL1 and
ELN downregulation to the fibulin-5 mutation is not so
obvious. The underlying mechanism might be indirect, as it
has been shown for the dysregulation induced by Marfan
mutations. Indeed, the Marfan syndrome, which is caused by
mutation in the FBN1 gene, has been linked to abnormal
transforming growth factor-b1 release due to poor retention
of the latent transforming growth factor-b1 on the microfibril
(Habashi et al., 2006; Brooke et al., 2008). To date, no such
signaling pathway has been elucidated in the cutis laxa
syndrome but this study shows that a gene reprogramming
process should occur and should be carefully examined.
In conclusion, this study shows that downregulation of
LOXL1 and potentially ELN in fibroblasts from a young cutis
laxa patient is a consequence of an abnormal DNMT activity.
Inhibition of such epigenetic enzymes offers new strategies to
counteract or attenuate part of the side defects of the fibulin-5
mutation in this case.
MATERIALS AND METHODS
Fibroblasts were isolated from skin biopsies (cutis laxa patient) or
surgical explants (healthy children). In all, 5 healthy strains were
used as controls: 2 male children (8 and 9 years of age) and 3 female
children (8 and 10 years of age). The study was approved by the
ethics committee of the Hopital La Pitie-Salpetriere (Paris, France)
and all experiments were performed in accordance with the
Declaration of Helsinki Principles. Informed consent was received.
For all experiments, cells were used below 20 population doubling.
The human promoter of LOXL1 consisted of the 2172/þ 1
region subcloned into the pGL3-basic vector upstream of the
luciferase gene. The different constructs are listed in Supplementary
Table S1 online. For promoter activity assessment, luciferase assays
were conducted by transfection into dermal fibroblasts from a
healthy child. Luciferase activity was expressed in relative light units
after normalizing the values to the b-galactosidase activity of each
sample.
Real-time reverse transcription-PCR experiments were performed
as previously described (Claus et al., 2008) using primer sequences
listed in Supplementary Table S1 online. Relative gene expression
was normalized with reference to the ACTB gene.
Electrophoretic mobility shift assay experiments were conducted
with nuclear extracts prepared from fibroblasts of healthy children.
The 415/353 region of the LOXL1 promoter encompassing the
two Sp-1 sites was labeled with (a-32P)adenosine 50-triphosphate
and used as probe. Specific and nonspecific competitions
assays were set up with 50 excess of unlabeled Sp-1 consensus
probe or activator protein-1 consensus probe, respectively, before
incubation with radiolabeled probe. For supershift, anti-Sp-1 anti-
body (Millipore SAS, Molsheim, France) was added to the nuclear
extract and radiolabeled probe for the last 10minutes of the
incubation period.
In chromatin immunoprecipitation experiments, chromatin was
isolated and immunoprecipitated as described (Debret et al., 2006).
An anti-Sp-1 antibody (sc-14027X; Santa Cruz Biotechnology,
Tebu-bio, Le Perray en Yvelines, France) or normal rabbit IgG
(Sigma-Aldrich, Saint-Quentin-Fallavier, France) as negative control
were used for immunoprecipitation. A positive control consisted of
nonimmunoprecipitated chromatin (inputs). The purified DNA
isolated by immunoprecipitation was analyzed by PCR using primers
specific for the proximal LOXL1 gene promoter (see Supplementary
Table S1 online).
For LOXL1 immunodetection, 30 mg of protein extract (see
Supplementary materials online for protein preparation) was
separated by 8% SDS-PAGE. Electrophoretically resolved bands
were then transferred to polyvinylidene difluoride membranes
(Immobilon; Millipore SAS) by electroblotting. Sp-1 was detected
from nuclear protein extracts (see electrophoretic mobility shift assay
Supplementary Protocol online for details). A total of 10 mg of protein
was separated by 10% SDS-PAGE and transferred on to nitrocellu-
lose membranes. The blots were incubated with an antibody raised
against Sp-1 (sc-14027; Santa Cruz Biotechnology) in a dilution of
1:5,000, or with an anti-LOXL1 antibody diluted 1:500 (Borel et al.,
2001) or an anti-b-actin polyclonal antibody (A5060, Sigma-Aldrich)
diluted 1:7,500. Blots were then incubated with peroxidase-
conjugated anti-rabbit IgG (Bio-Rad, Marnes-La-Coquette, France)
before detection using an enhanced chemiluminescent kit (Perkin
Elmer, Courtaboeuf, France).
Untreated 5aza-dC (5 μM)
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Figure 6. Lysyl oxidase-like-1 (LOXL1) and elastin (ELN) expressions are
restored in cutis laxa cells treated by 5-aza-20-deoxycytidine (5aza-dC).
Subconfluent skin fibroblasts from a cutis laxa patient were treated or not with
5aza-dC. LOXL1, LOX, fibrillin-1 (FBN1), and ELN transcripts from cultures at
2 days after confluence were analyzed by real-time reverse transcription PCR
(RT-PCR) and normalized to ACTB. Results represent the average of two
independent experiments performed in triplicate and are expressed as
mean±SEM (**Po0.01, Student’s t-test).
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Bisulfite modification was conducted based on the principle that
sodium bisulfite treatment converts unmethylated cytosines to uracil
by a deamination reaction, leaving methylated cytosines unchanged.
Methylated and unmethylated DNA sequences thus become
distinguishable after bisulfite conversion by sequence-specific
primers (see Supplementary Table S1 online).
Detailed methodological information is available in Supplemen-
tary Materials and Methods online.
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